Best Life Sciences Companies in North Holland, Netherlands
The 115 best Life Sciences companies in North Holland, Netherlands in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Leyden Labs.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in North Holland
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Leyden Labs Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa | $200M | 12 mo ago | Series B | 80 | Dinko Valerio Co-founder & Executive Chairman | WordPressMySQLPHP+20 | — | — |
| 2 | NewAmsterdam Pharma Developer of transformative therapeutic solutions for cardio-metabolic diseases | $196M | 65 mo ago | Public | 17 | John Kastelein Founder & CSO | DrupalApple iCloud MailPHP+26 | 124 patents CETP inhibitor drug development and formulation, especially obicetrapib for cardiovascular and dementia therapy | 2 awards |
| 3 | VectoryTx Developer of therapeutics for neurodegenerative and muscular disorder | $176M | 31 mo ago | Series A | 78 | Sander Van Deventer Chief Executive Officer | Cart FunctionalitySquarespace CommerceSquarespace+16 | — | 3 job openings |
| 4 | NorthSea Therapeutics Developer of structurally engineered fatty acids for metabolic disease treatment | $149M | 54 mo ago | Series C | 4 | David Fraser Co-Founder | — | 4 patents Novel fatty acid derivatives for metabolic and gastrointestinal disease therapies | — |
| 5 | UniQure Developer of gene-based therapies for patients with genetic or acquired diseases | $111M | 62 mo ago | Public | 501 | Matthew Kapusta CEO | Apple iCloud MailMicrosoft 365GSAP+15 | 328 patents Engineering AAV vectors and liver-specific promoters for gene therapy applications | — |
| 6 | LUMICKS Manufacturer of optical tweezers for single molecule analysis instruments | $93M | 20 mo ago | Series D | 263 | Andrea Candelli Co-Founder | Webflow EcommerceWebflowMemberStack+25 | — | 1 launch |
| 7 | Avidicure Developer of immunotherapies for cancer therapeutics | $50M | 13 mo ago | Seed | — | Govert Schouten Co-Founder | WordPressMySQLPHP+10 | 8 patents Engineered cytokine/antibody fusion proteins for NK‑cell cancer immunotherapy | — |
| 8 | Peptone Provider of an AI based protein analysis platform for research and development | $42M | 48 mo ago | Series A | 31 | — | WordPressApple iCloud MailGoogle Workspace+19 | — | — |
| 9 | Citryll Targeting neutrophil extracellular traps for autoimmune diseases | $38M | 18 mo ago | Series B | 19 | Eduardo Bravo Chief Executive Officer | WordPressMySQLPHP+20 | 25 patents Anti‑citrullinated histone antibodies for autoimmune disease diagnostics and therapeutics | — |
| 10 | Avanzanite Developer of therapeutics to treat rare diseases | $37M | 7 mo ago | Series A | — | Anant Murthy Co-Founder and Board Advisor | WordPressApple iCloud MailMicrosoft 365+14 | — | 1 job opening · 1 partnership · 1 expansion |
| 11 | Kiadis Pharma Developer of cell-based immunotherapy products for the treatment of blood cancers | $33M | 68 mo ago | Acquired | 103 | — | — | 29 patents Manufacturing expanded NK cell therapies and validating flow cytometry analytical methods. | — |
| 12 | myTomorrows Platform provides access to drugs in development to patients and physicians | $22M | 7 mo ago | Series C | 92 | Ronald Brus Co-Founder & CEO | WagtailWordPressPython+35 | — | 3 job openings |
| 13 | Synerkine Pharma Developer of therapeutics to treat osteoarthritis and chronic pain | $13M | 32 mo ago | Series A | 2 | Erik Hack Co-Founder | — | 26 patents Engineered cytokine fusion proteins for targeted immunotherapy and anti‑inflammatory applications | — |
| 14 | Dezima Pharma Develop treatments for cardiovascular diseases related to dyslipidemia | $13M | 159 mo ago | Acquired | — | Rob De Ree Ex-CEO | — | 78 patents CETP inhibitor cardiovascular drugs and tetrahydroquinoline intermediate synthesis for pharmaceuticals | — |
| 15 | Photanol Provider of technology for light-powered bio-production of chemicals | $9M | 54 mo ago | Series A | 39 | — | — | 27 patents Photosynthetic microbial synthesis of platform chemicals (propylene, glycolate, 1,3‑propanediol, erythritol). | — |
| 16 | BMEYE Non-invasive techniques for cardiovascular monitoring | $9M | 200 mo ago | Acquired | — | William Bednarski CEO | — | 23 patents Non‑invasive cardiovascular and oxygen delivery monitoring devices and analytics | — |
| 17 | ORCA Therapeutics Provider of virus mediated immunotherapy for cancer | $9M | 121 mo ago | Series A | 4 | — | — | 9 patents Patents concentrated in chemistry & materials | — |
| 18 | Self-screen Provider of self-screening solutions for cervical cancer | $8M | 77 mo ago | Funding Raised | — | — | — | 95 patents Epigenetic DNA‑methylation diagnostic assays for HPV‑related gynecological and anogenital cancers | — |
| 19 | Scenic Biotech Developer of therapeutics for cancer and rare genetic diseases | $7M | 51 mo ago | Series A | 48 | Thijn Brummelkamp Founder & MD | WordPressPleskMySQL+17 | 10 patents Small‑molecule inhibitors of lysosomal enzymes (PLA2G15, ABHD18, GALK1) for disease therapy | — |
| 20 | Confocal Developer of improved confocal microscope | $6M | 20 mo ago | Series A | 16 | Pim Vos CEO | — | 11 patents Advanced re-scan optical systems for high‑precision confocal microscopy imaging | — |
| 21 | CimCure Developer of immune therapy for treating solid tumors | $5M | 48 mo ago | Seed | 8 | Diederik Engbersen Chief Executive Officer | — | — | — |
| 22 | Haermonics A drainage and flushing system for postoperative pericardial flushing | $4M | 46 mo ago | Series A | 9 | Johan Manshanden Co-Founder & CSO | — | 8 patents Surgical irrigation and drainage systems for body cavities, especially pericardial flushing | — |
| 23 | Optics11 Life Online e-distributor offering scientific equipment | $4M | 8 mo ago | Series A | 55 | Davide Iannuzzi Co-Founder | Cart FunctionalityWordPressMySQL+31 | — | — |
| 24 | Kreatech Developer of novel FISH probes for detection and quantification | $3M | 198 mo ago | Acquired | — | Kees Moonen CEO | — | — | — |
| 25 | Audion Therapeutics Developing drugs treating hearing loss | $3M | 129 mo ago | Series B | — | Rolf Jan Rutten CEO | — | 43 patents Small‑molecule inhibitors targeting the Notch signaling pathway for therapeutic applications. | — |
| 26 | Caelus Health Developer of microbiota-based products to address cardiometabolic disorders | $3M | 112 mo ago | Series A | 5 | Max Nieuwdorp Co-Founder | — | — | — |
| 27 | Amsterdam Scientific Instruments Leveraging particle physics for innovative imaging applications | $2M | 103 mo ago | Seed | 27 | — | — | — | 2 launchs |
| 28 | Bac Discovers, develops and manufactures separation and affinity purification products | $2M | 212 mo ago | Acquired | — | Amar Patel CEO & President | — | 56 patents Engineered single-domain antibody fragments targeting IgG CH1 for affinity purification | — |
| 29 | Phlox Therapeutics Developer of gene therapy to cure genetic heart diseases | $2M | 19 mo ago | Seed | 4 | Eva Rooij Co-Founder & CSO | — | — | — |
| 30 | Amazec photonics Provider of a temperature-sensing platform for cardiovascular monitoring | $2M | 28 mo ago | Seed | 2 | Pim Kat CEO | — | 6 patents Optical non‑invasive monitoring of cardiovascular and respiratory parameters in mammals. | — |
| 31 | Ansana Developer of sterilization devices for operating rooms and pharma companies | $2M | 8 mo ago | Seed | — | Dominique Surinx CEO | — | — | — |
| 32 | ELLOGON.AI Provider of AI-based platform for personalized cancer immunotherapy | $1M | 27 mo ago | Seed | — | Efstratios Gavves Co-Founder | — | — | — |
| 33 | Nostics Provider of covid 19 testing services | $1M | 33 mo ago | Funding Raised | 28 | Rochelle Niemeijer Co-Founder | WordPress Block EditorwpBakeryElementor+23 | 14 patents Rapid antimicrobial susceptibility testing of pathogens in body fluids using SERS-based analysis | 2 internships |
| 34 | PacingCure Developer of implantable pacemaker therapies | $334K | 32 mo ago | Seed | — | Gerard Boink CEO | — | — | — |
| 35 | Respiosa Developer of a surgically implanted solution for tongue-based obstructive sleep apnea | $264K | 6 mo ago | Seed | 1 | — | — | — | — |
| 36 | Frame Therapeutics Developer of immunotherapies for cancer treatment | $111K | 76 mo ago | Acquired | 13 | Bob Lowenberg Co-Founder | — | — | — |
| 37 | Cytofind Developer of diagnostic test to detect circulating tumor cells | $109K | 113 mo ago | Funding Raised | — | Wilhelm Huck ex-Co-Founder | — | — | — |
| 38 | Digi.Bio Provider of an AI-powered automated liquid handling platform | $100K | 105 mo ago | Seed | 11 | Federico Muffatto Co-Founder & CEO | — | — | — |
Top 12 Life Sciences companies in North Holland
#1
Series B · Amsterdam, North Holland · founded 2020 · 80 employees$200Mraised▾
Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa. It develops nasal sprays that stop initial infection, prevent onward transmission, protect broadly against existing and new viruses, and provide universal protection, regardless of an individual’s immune history or comorbidities. The company focuses on harnessing mucosal immunity and broad protection by delivering antibodies directly to the nasal mucosa for immediate anti-viral protection. It develops active substances that target regions that lend themselves to lasting protection against multiple strains and entire virus families.
- Jun 2025Venture Debt$22.8M
- Jan 2025Series B$70M
- Jan 2022Series B$140M
- Mar 2021Series A$47.3M
#2
Series A · Amsterdam, North Holland · founded 2021$37.1Mraised▾
Developer of therapeutics to treat rare diseases. The company focuses on the development of orphan medicine for the treatment of an ultra-rare ophthalmologic disease which includes Acanthamoeba Keratitis (AK) a devastating, highly resistant eye infection.
- Nov 2025Series A$37.1M
#3
Series C · Amsterdam, North Holland · founded 2012 · 92 employees$22.3Mraised▾
myTomorrows offers a platform for early drug access to patients and doctors. The platform connects patients, doctors, and drug companies. It provides information on medical conditions, related clinical trials, and early access programs through its platform. The platform facilitates requests for drugs in development and supplies diagnostic tests.
- Nov 2025Series C$29M
- Jan 2017Series B$10.7M
- Nov 2014Series A$5.6M
- Feb 2014Seed$2.2M
#4
Seed · Amsterdam, North Holland · founded 2022$50Mraised▾
Developer of immunotherapies for cancer therapeutics. It offers AVC-Boosters supercharged antibodies that boost the number and function of NK cells at the tumor, cause activation of the full immune system and provide broad TME-resistant anti-tumor responses.
- Apr 2025Seed$50M
#5
Series D · Amsterdam, North Holland · founded 2014 · 263 employees$93.4Mraised▾
Manufacturer of optical tweezers for single-molecule analysis instruments. The product portfolio of the company includes C-Trap, an integrated system with optical tweezers, a confocal microscope, and a microfluidic system to analyze protein folding, DNA repair, DNA organization, Protein polymer, and filaments. Its product, AFS-acoustic force spectroscopy (a single molecule manipulation system), and u-Flux (an integrated microfluidic system) are used in performing experiments in a laminar flow environment.
- Oct 2024Venture Debt$21.9M
- Jan 2023Grant (prize money)$294.3K
- Sep 2022Grant (prize money)$48.7K
- Apr 2021Series D$93.4M
#6
Series A · Amsterdam, North Holland · founded 2011 · 55 employees$4Mraised▾
Online e-distributor offering scientific equipment. The company offers features like touch & go interface, semi-automated, modular microscopy capabilities, automatic find surface function, and more. The nanoindenters have various applications like drug screening, disease diagnosis, regenerative medicine, and more.
- Oct 2025Series A$4M
- Jan 2019Grant (prize money)$304.4K
- Nov 2016Grant (prize money)$152.5K
#7
Series B · Amsterdam, North Holland · founded 2015 · 19 employees$37.7Mraised▾
Citryll is a US-based biopharma developing antibody therapeutics to target neutrophil extracellular traps for autoimmune diseases like Rheumatoid Arthritis (RA), Colitis and others. The therapeutics work by extinguishing the source of auto-antigens and neutrophil extracellular trap (NET) derived toxic molecules instead of broadly targeting inflammation. The company is a spin-out from ModiQuest. Citryll has a proprietary toolbox to study NET biology and protein citrullination and their role in human pathologies. Citryll’s lead programme tACPA, targets the formation of neutrophil extracellular traps, called NETs. These drugs work by interfering with the formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by peptidyl-arginine deiminase (PAD) enzymes.
- Dec 2024Series B$89.8M
- Jul 2020Series B$20.8M
- Jul 2020Grant (prize money)—
- Jul 2019Series A$16.9M
#8
Seed · Amsterdam, North Holland · founded 2022$1.8Mraised▾
Developer of sterilization devices for operating rooms and pharma companies. The company offers a smart sterilization container that is equipped with sensors that monitor the sterilization process and reduces surgical site infections, eliminating plastic consumables for hospitals.
- Sep 2025Seed$1.8M
#9
Seed · Amsterdam, North Holland · founded 2022 · 1 employees$264.1Kraised▾
Developer of a surgically implanted solution for tongue-based obstructive sleep apnea. The company's implant prevents the tongue from collapsing into the airway during sleep. The implant is surgically inserted and adjusted after implantation. The solution aims to provide a permanent and well-tolerated treatment option for the condition.
- Dec 2025Seed$264.1K
#10
Series A · Amsterdam, North Holland · founded 2020 · 78 employees$175.6Mraised▾
Developer of therapeutics for neurodegenerative and muscular disorders. The products contain next-generation viral vectors that target specific cell types and subcellular compartments while evading the host immune response. The company is developing therapeutics based on an AAV gene therapy platform, antibody, and RNA-targeted degradation technologies.
- Nov 2023Series A$138M
- Jun 2021Seed$37.6M
#11
Series A · Amsterdam, North Holland · founded 2016 · 16 employees$5.7Mraised▾
Developer of improved confocal microscope. The company engages in developing an improved camera-based RCM (re-scanning confocal microscope) that offers high-resolution good signal-to-noise ratio. It has a new super-resolution technique based on standard confocal microscopy extended with an optical (re-scanning) unit that projects the image directly on a CCD-camera, improved lateral resolution (170 nm at 488 nm light), and strongly improved sensitivity,
#12
Seed · Naarden, North Holland · founded 2022 · 4 employees$2Mraised▾
Developer of gene therapy to cure genetic heart diseases. The lead program PHL-001 is a RNA-based therapeutic product that targets laminopathies, a rare inherited cardiomyopathy, and therapy resistant heart-failures.
- Nov 2024Seed$2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.